Filtered By:
Specialty: OBGYN
Cancer: Breast Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 17 results found since Jan 2013.

Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study
Conclusions:The risks of cardiovascular disease and cancer were not elevated among postmenopausal women using vaginal estrogens, providing reassurance about the safety of treatment. Objective: To determine the association between use of vaginal estrogen and risk of a global index event (GIE), defined as time to first occurrence of coronary heart disease (CHD), invasive breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer, or death from any cause. Methods: For this prospective observational cohort study, we used data from participants of the Women's Health Initiative Observat...
Source: Menopause - December 22, 2017 Category: OBGYN Tags: Original Articles Source Type: research

Managing menopause.
Authors: Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W, Menopause and Osteoporosis Working Group, Fortier M, Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Graves L, Guthrie B, Khan A, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W Abstract OBJECTIVE: To provide updated guidelines for health care providers on the management of menopause in asymptomatic healthy women as well as in women presenting with vasomotor or urogenital symptoms and on considerations related to cardiovascular disease, breast cancer, urogynaecology, and sexuality. OUTCOMES: Lifestyle...
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - December 2, 2014 Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research

Lessons Learned From the Women's Health Initiative Trials of Menopausal Hormone Therapy.
Abstract We re-evaluate the Women's Health Initiative findings and their implications for clinical practice. Menopausal hormone therapy (HT) was effective for relief of vasomotor symptoms, and the risk of coronary heart disease (CHD) tended to be reduced in women close to menopause compared with the increased risk in women more distant from menopause. In recently menopausal women, short-term absolute risks of stroke and venous thromboembolism were small. Estrogen plus progestin therapy, but not estrogen therapy, increased the risk of breast cancer with a suggestion of greater risk when initiated close to the menop...
Source: Obstetrics and Gynecology - January 1, 2013 Category: OBGYN Authors: Rossouw JE, Manson JE, Kaunitz AM, Anderson GL Tags: Obstet Gynecol Source Type: research

Women's Health Initiative estrogen plus progestin clinical trial: a study that does not allow establishing relevant clinical risks
Conclusions: The differences in RMST for the outcomes of the WHI study are too small to establish clinical risks related to hormone therapy use.
Source: Menopause - December 1, 2015 Category: OBGYN Tags: Original Articles Source Type: research

Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial
Conclusions: In black postmenopausal women with prior hysterectomy, estrogen alone significantly reduced breast cancer incidence with no adverse influence on CHD, venous thromboembolism, or all-cause mortality. Favorable estrogen-alone global index effects in younger black women warrant further study.
Source: Menopause - January 28, 2017 Category: OBGYN Tags: Original Articles Source Type: research

Development of a comprehensive health-risk prediction tool for postmenopausal women
Conclusion: This study represents the first large-scale study to develop a risk prediction calculator that yields health risk prediction for several outcomes simultaneously. Development of this tool is a first step toward enabling women to prioritize interventions that may decrease these risks. Video Summary:http://links.lww.com/MENO/A463.
Source: Menopause - December 1, 2019 Category: OBGYN Tags: Original Articles Source Type: research

The severity of vasomotor symptoms and number of menopausal symptoms in postmenopausal women and select clinical health outcomes in the Women's Health Initiative Calcium and Vitamin D randomized clinical trial
This study evaluated whether vasomotor symptom (VMS) severity and number of moderate/severe menopausal symptoms (nMS) were associated with health outcomes, and whether calcium and vitamin D (CaD) modified the risks. Methods: The Women's Health Initiative CaD study was a double blind, randomized, placebo-controlled trial, which tested 400 IU of 25-hydroxyvitamin-D and 1,000 mg of calcium per day in women aged 50 to 79 years. This study included 20,050 women (median follow-up of 7 y). The outcomes included hip fracture, colorectal cancer, invasive breast cancer, all-cause mortality, coronary heart disease, stroke, cardi...
Source: Menopause - October 30, 2020 Category: OBGYN Tags: Original Studies Source Type: research

Long‐term safety of unopposed estrogen used by women surviving myocardial infarction: 14‐year follow‐up of the ESPRIT randomised controlled trial
ConclusionsThese results suggest that unopposed estrogen may be used safely by women with an intact uterus surviving a first myocardial infarction.
Source: BJOG: An International Journal of Obstetrics and Gynaecology - February 18, 2014 Category: OBGYN Authors: N Cherry, R McNamee, A Heagerty, H Kitchener, P Hannaford Tags: Original Article Source Type: research

Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial.
CONCLUSIONS: These results suggest that unopposed estrogen may be used safely by women with an intact uterus surviving a first myocardial infarction. PMID: 24533510 [PubMed - as supplied by publisher]
Source: BJOG : An International Journal of Obstetrics and Gynaecology - February 18, 2014 Category: OBGYN Authors: Cherry N, McNamee R, Heagerty A, Kitchener H, Hannaford P Tags: BJOG Source Type: research

FDA Approval of Paroxetine for Menopausal Hot Flushes
ABSTRACT: In June 2013, the Food and Drug Administration (FDA) approved paroxetine (Brisdelle, Noven) for the treatment of moderate to severe hot flushes (vasomotor symptoms) associated with menopause. Brisdelle is the only nonhormonal treatment approved by the FDA for this indication. Prior to approval of Brisdelle, FDA-approved treatments for hot flashes were hormones containing either estrogen alone or estrogen plus a progestin. Hormonal therapy is highly effective for treating vasomotor symptoms. However, the use of hormonal therapy dropped substantially after initial findings of the Women’s Health Initiative randomi...
Source: Obstetrical and Gynecological Survey - October 1, 2014 Category: OBGYN Tags: Gynecology: Office Gynecology Source Type: research

Prevalence of menopausal symptoms among mid-life women: findings from electronic medical records
Conclusion: Our findings provide recent data on the types of menopausal symptoms experienced by mid-life women prescribed HT. Electronic medical records may be a rich source of data for future studies of menopausal symptoms in this population.
Source: BMC Women's Health - August 13, 2015 Category: OBGYN Authors: Matthew SussmanJeffrey TrocioCraig BestSebastian MirkinAndrew BushmakinRobert YoodMark FriedmanJoseph MenzinMichael Louie Source Type: research

Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study
Conclusions: The summary index of risks versus benefits was similar for oral CEE versus oral or transdermal E2-containing regimens. CEE + P containing less than 0.625 mg/d of CEE (vs 0.625 mg/d) for less than 5 years appeared safer.
Source: Menopause - September 23, 2017 Category: OBGYN Tags: Original Articles Source Type: research

Hormone therapy in menopausal women with fibroids: is it safe?
Menopause is an important transition in the life of women. It has been estimated that by the year 2030, worldwide 1.2 billion women will be menopausal. The most bothersome symptoms of menopause are believed to be due to declines in estrogen levels in postmenopausal women. Thus, hormone therapy is an effective treatment option for menopausal women, although prolonged use of hormone therapy is associated with a slightly increased risk of breast cancer, thromboembolism, and stroke. A literature search for studies evaluating the effects of hormone therapy in menopausal women with asymptomatic fibroids demonstrated variable eff...
Source: Menopause - July 26, 2018 Category: OBGYN Tags: Personal Perspective Source Type: research

Pattern of mortality after menopausal hormone therapy: long-term follow-up in a population based cohort.
CONCLUSIONS: In this long-term follow-up study, taking hormones during menopause was not associated with overall mortality among middle-aged women. Investigating cause-specific mortality revealed significant albeit weak associations differential according to both causes of death and over time underlining the importance of carefully considering individual risks and duration of treatment when making decisions on hormone therapy. This article is protected by copyright. All rights reserved. PMID: 30106241 [PubMed - as supplied by publisher]
Source: BJOG : An International Journal of Obstetrics and Gynaecology - August 14, 2018 Category: OBGYN Authors: Holm M, Olsen A, Au Yeung SL, Overvad K, Lidegaard Ø, Kroman N, Tjønneland A Tags: BJOG Source Type: research